World Lung Cancer Day (August 1st ) Commemorates, Celebrates, and Supports Those Impacted by Lung CancerRead Now
GLENVIEW, Ill. (July 29, 2016) – On World Lung Cancer Day on August 1, the American College of Chest Physicians (CHEST), alongside members of the Forum of International Respiratory Societies (FIRS) commemorates, celebrates and supports those impacted by lung cancer. FIRS joins the grassroots efforts of the lung cancer community to raise awareness about lung cancer and its global impact, creating an educational movement of understanding lung cancer risks as well as early treatment around the world.
Lung cancer is the most common cancer worldwide, accounting for 1.8 million new cases in 2012, and is responsible for nearly one in five cancer deaths according to the World Health Organization. Lung cancer claims more lives yearly than breast, colon and prostate cancers combined. According to the American Cancer Society, an estimated 224,390 new cases of lung cancer are expected to be diagnosed in 2016, accounting for about 14% of all cancer diagnoses in the United States alone.
World Lung Cancer Day 2016: Honor, Unite, Inspire highlights the many risk factors to be aware of in order to detect lung cancer at the earliest stage possible. While most understand that smoking is the single greatest risk factor for lung cancer, other lesser known risk factors include environment and genetics. Environmental exposure to radon, asbestos, arsenic, beryllium and uranium have all been linked to lung cancer. The risk of lung cancer also increases with a history of cancer in another part of the body, age, family history, radiation to the chest area and lung diseases like COPD.
The initiative also aims to shed light on key symptoms and screening options. Symptoms include change in mucus, chest or back pain, coughing up blood and difficulty swallowing. Tests that may be used to diagnose lung cancer include chest X-rays, CT and PET scans, bronchoscopy and needle biopsies. If you are a current or former smoker and over age 55, you may be a candidate for a low- dose CT scan screening that can offer early detection of lung cancer, potentially at its earliest stages.
“Treatment options for lung cancer have significantly advanced over the past few years and survival rates are increasing. We’re hopeful the World Lung Cancer Day efforts will help to continue to raise awareness of risks and increase early detection for the best possible outcomes,” said Dr. Gerard Silvestri, President-Elect of the American College of Chest Physicians.
More than 70,000 global FIRS members have united in support of World Lung Cancer Day, including member organizations: CHEST, Asociación Latinoamericana del Thorax (ALAT), the American Thoracic Society, the Asian Pacific Society of Respirology, the European Respiratory Society, the International Union Against Tuberculosis and Lung Disease and the Pan African Thoracic Society.
Patients, families and caregivers can download free educational resources and learn more about lung cancer, risk factors, screenings and treatment options by visiting http://www.chestnet.org/WLCD.
CHEST is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research and team-based care. Its mission is to champion the prevention, diagnosis and treatment of chest diseases through education, communication and research. CHEST serves as an essential connection to clinical knowledge and resources for its 19,000 members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For more information, visit chestnet.org.
About the Forum of International Respiratory Societies
FIRS is an organization consisting of the world’s leading international respiratory societies working together to improve lung health globally: American Thoracic Society, CHEST, Asociación Latinoamericana De Tórax, Asian Pacific Society of Respirology, European Respiratory Society, International Union Against Tuberculosis and Lung Diseases and the Pan African Thoracic Society. The goal of FIRS is to unify and enhance efforts to improve lung health through the combined work of its more than 70,000 members globally.
Contact: Kristi Bruno, firstname.lastname@example.org
Amanda Chen is a health researcher at Self Care Catalysts, a health research company based in Toronto and San Francisco.
She is conducting a self-funded, proprietary research on the Cancer Patient Journey. She is looking for patients to participate in a 30-minute online survey. This survey will explore the journey of cancer patients as they cope with their illness, their treatment experience, decision making process, the role of their caregivers and supporters, and more. The insights drawn from this survey will be used to develop health solutions and programs that better meet patients’ needs. All participants will be compensated for their time.
You can download the .PDF file below to learn more. You can also contact Amanda directly at email@example.com.
Sonia Williams of Spotlite Radio interviews President and CEO of The Joan Gaeta Lunt Cancer Fund, Joe Gaeta. From April 15th, 2014.
On February 18, don't miss the leaders and armies of lung cancer advocacy groups as they align like the stars to discuss efforts to achieve the goal and raise funds to commit to this "cost of living with lung cancer."
Join members of the Bonnie J. Addario Lung Cancer Foundation, American Lung Association, Dusty Joy Foundation, Lung Cancer Foundation of America (LCFA), and Lungevity for an unprecedented collaboration in the fight to end lung cancer.
"Now that we've heard what the experts have to say, what can we do together to move the needle forward?"
- Danielle Beltramo - Hicks
Whether you join us in ALCF’s Living Room or attend remotely through Livestream on your computer, you will be informed about Living with Lung Cancer.
If you are having trouble getting the live stream working, click here for help and troubleshooting tips.
The Patient Handbook, “Navigating Lung Cancer, 360 Degrees of Hope,” is the first-ever comprehensive, up-to-date patient resource for Lung Cancer.
For a hard copy of the handbook please email firstname.lastname@example.org or click below to download a copy.
The brightest minds in research, academics and advocacy unite at the Lung Cancer Living Room.
Published on November 5, 2013 by The Bonnie J. Addario Lung Cancer Foundation
SAN CARLOS, CA, Nov. 5, 2013 /PRNewswire-USNewswire/ -- The Bonnie J. Addario Lung Cancer Foundation (ALCF) is proud to present The Next Decade in Lung Cancer, a three-part series of the Lung Cancer Living Room, the nation's premiere live-streamed support group for patients, family and friends.
"We are asking the big question. What will it take to make lung cancer a chronically managed disease in the next 10 years?" said Bonnie J. Addario, lung cancer survivor and founder of the ALCF. "The Next Decade in Lung Cancer offers a glimpse into the future from the perspective of researchers, advocates and most importantly patients."
The three-part series will unite industry leaders in medicine, research and technology who will discuss the latest advancements and breakthroughs in lung cancer. Advocacy and policy agencies and foundations will also discuss access, information, education and needed legislative changes.
The series, which will take place over the next three months, kicks off on November 10, 2013 at 2 p.m. (PST). Guests who attend the Living Room in-person will have the opportunity to network with other patients and with the guest speakers listed below. Online guests can also participate through the live stream, asking questions and sending comments via a live chat function. The session also airs at a later date locally on Peninsula TV.
The ALCF regularly hosts the Living Room on the third Tuesday of every month and the program is live-streamed online. It is the nation's premier lung cancer support group for lung cancer patients and their families, offering expert opinion and advice not found anywhere else. Visit www.ustream.com and select the Lung Cancer Living Room Support Group channel to see the video archive, including full length videos and 20-minute condensed highlighted versions, available the week after the group meets.
The patient empowerment educational series is made possible through funding partners: Biodesix, Bristol-Myers Squibb, Celgene, Genentech and The Safeway Foundation.
About The Bonnie J. Addario Lung Cancer Foundation
The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest philanthropies (patient-founded, patient-focused, and patient-driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment. The Foundation works with a diverse group of physicians, organizations, industry partners, individuals, survivors, and their families to identify solutions and make timely and meaningful change. The ALCF was established on March 1, 2006 as a 501c(3) non-profit organization and has raised more than $10 million for lung cancer research and patient services.
Read more here.
The Bonnie J. Addario #LungCancer Foundation's 360 Community Hospital Program Improving Individualized Standard of Care for PatientsRead Now
Pilot program already showing positive patient outcomes, with ultimate goal to increase the lung cancer survival rate.
SAN CARLOS, CALIF., JUNE 20, 2013 — /PRNewswire-USNewswire/ -- The Bonnie J. Addario Lung Cancer Foundation is creating a new patient-focused approach to standard of care for lung cancer with the launch of the Patient 360 Community Hospital Program. The program uses a collaborative, multi-disciplinary model to provide an individualized approach to care, giving the patient access to the newest and most effective diagnostic and therapeutic techniques for their specific needs.
"What we're finding is by using a team approach to individualized care we can begin to incrementally increase the survival rate of people diagnosed with lung cancer," said Bonnie J. Addario, a stage 3B survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (LCF). "Because 80 percent of patients receive treatment at their local community hospital, these are the centers where the greatest good can be done for the greatest number."
Working with an elite team of pathologists and specialists to create an unsurpassed paradigm for lung cancer treatment, the LCF is in essence creating lung-specific centers of excellence in the community hospital setting. The program ensures that every patient receives molecular testing, combined with a multi-disciplinary team approach and selected treatment options unique to the patient's needs.
"The 360 Program's multidisciplinary approach is unique because it coordinates the standard of care for patients individually, giving each patient what's right for them." Addario said. "So the oncologist, the radiation oncologist, the pathologist, the pulmonologist, and the surgeon are all communicating and collaborating, not just with academic, industry and technology, but internally as well."
During the first six months of the pilot stage of the program, preliminary metrics and data have shown that patient outcomes have improved dramatically.
The program is rigid in its standard of treatment. Every patient in the pilot 360 program received molecular testing to better determine personalized treatments, as will be the case for all future patients as the program expands to more community hospitals in the coming years. Three new hospitals are expected to enlist by the end of 2013 and 30-50 by the end of 2015.
The program's process focuses on early detection, diagnosis, treatment and treatment monitoring, and patient follow up. Critical in the program's standard of care is ensuring all patients receive molecular testing, which uses DNA, RNA and proteins to test for specific states of disease. In lung cancer, molecular testing is used to determine potential patient response to targeted therapy.
The LCF has received generous support from a number of distinguished industry partners, including GE Healthcare, Pfizer and Boehringer-Ingelheim. GE Healthcare provided in-kind services from its oncology solutions division to help create the program's flow and metrics. The LCF is working with Boehringer-Ingelheim and Pfizer in partnership to broaden the overall awareness of multi-disciplinary collaborations that incorporate personalized testing to initiate timely and appropriate lung cancer treatments. Boehringer-Ingelheim also leads the letstestnow.com campaign, set up to improve patient outcomes through a multidisciplinary approach to biomarker testing in advanced non-small cell lung cancer.
"Every community hospital that joins us and implements this new multi-disciplinary, patient-centric approach to standard of care will be given a formal seal of excellence awarded by the LCF, signifying that no lung cancer patient is left behind," Addario said.
The pilot program launches during a time when an estimated 228,190 new cases of lung cancer will be diagnosed in the United States this year. The American Cancer Society also estimates 159,480 Americans will die from the disease this year.
The facts about Lung Cancer cannot continue to go unnoticed:
"The Foundation is powering progress through ground-up initiatives, educating patients to identify solutions and make timely and meaningful change," Addario said. "The LCF is empowering patients to take a seat at the table wherever discussions are being made about their care. We are committed to improving the standard of care and believe that chronically managed lung cancer using molecular testing to determine personalized therapies is the future of lung cancer treatment and the pathway to increasing the survival rate."
About the Bonnie J. Addario Lung Cancer Foundation
The Bonnie J. Addario Lung Cancer Foundation is one of the largest philanthropies (patient-founded, patient-focused, and patient-driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment. The Foundation works with a diverse group of physicians, organizations, industry partners, individuals, survivors, and their families to identify solutions and make timely and meaningful change. BJALCF was established on March 1, 2006 as a 501c(3) non-profit organization and has raised more than $10 million for lung cancer research.
SOURCE Bonnie J. Addario Lung Cancer Foundation
We are extremely proud to be an affiliate of the Bonnie J. Addario #LungCancer Foundation @End_Lung_CancerRead Now
Click on image below for a larger view.